Literature DB >> 24357063

Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner.

Jialing Bao1, Juan Xiao, Yingying Mao, X Long Zheng.   

Abstract

OBJECTIVE: ADAMTS13 (A Disintegrin And Metalloprotease with Thrombospondin type 1 repeats, 13) cleaves von Willebrand factor (VWF), thereby inhibiting thrombus formation. Proteolytic cleavage relies on the amino-terminal (MDTCS) domains, but the role of the more distal carboxyl-terminal domains of ADAMTS13 is not fully understood. A previous study demonstrated the presence of multiple surface-exposed free sulfhydryls on ADAMTS13 that seemed to interact with those on VWF under shear. Here, we determined the physiological relevance of such an interaction in antithrombotic responses under flow. APPROACH AND
RESULTS: A microfluidic assay demonstrated that a carboxyl-terminal fragment of ADAMTS13, comprising either 2 to 8 thrombospondin type 1 (TSP1) repeats and CUB domains (T2C) or 5 to 8 Thrombospondin type 1 (TSP1) repeats and CUB domains (T5C), directly inhibited platelet adhesion/aggregation on a collagen surface under arterial shear. In addition, an intravital microscopic imaging analysis showed that the carboxyl-terminal fragment of ADAMTS13 (T2C or T5C) was capable of inhibiting the formation and elongation of platelet-decorated ultra large (UL) VWF strings and the adhesion of platelets/leukocytes on endothelium in mesenteric venules after oxidative injury. The inhibitory activity of T2C and T5C on platelet aggregation and ULVWF string formation were dependent on the presence of their surface free thiols; pretreatment of T2C and T5C or full-length ADAMTS13 with N-ethylmaleimide that reacts with free sulfhydryls abolished or significantly reduced its antithrombotic activity.
CONCLUSIONS: Our results demonstrate for the first time that the carboxyl terminus of ADAMTS13 has direct antithrombotic activity in a free-thiol-dependent manner. The free thiols in the carboxyl-terminal domains of ADAMTS13 may also contribute to the overall antithrombotic function of ADAMTS13 under pathophysiological conditions.

Entities:  

Keywords:  ADAMTS13; animal model; arterial thrombosis; thrombotic thrombocytopenic purpura; von Willeband factor

Mesh:

Substances:

Year:  2013        PMID: 24357063      PMCID: PMC4013287          DOI: 10.1161/ATVBAHA.113.302547

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

1.  ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.

Authors:  Jing-fei Dong; Joel L Moake; Aubrey Bernardo; Kazuo Fujikawa; Chalmette Ball; Leticia Nolasco; José A López; Miguel A Cruz
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

2.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

3.  Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice.

Authors:  Jing Huang; David G Motto; David R Bundle; J Evan Sadler
Journal:  Blood       Date:  2010-07-19       Impact factor: 22.113

Review 4.  Thrombotic thrombocytopenic purpura: the systemic clumping "plague".

Authors:  Joel L Moake
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

5.  Flow-based measurements of von Willebrand factor (VWF) function: binding to collagen and platelet adhesion under physiological shear rate.

Authors:  Birte Fuchs; Ulrich Budde; Andrea Schulz; Craig M Kessler; Claudine Fisseau; Christoph Kannicht
Journal:  Thromb Res       Date:  2009-10-24       Impact factor: 3.944

6.  Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor.

Authors:  Sheng-Yu Jin; Christopher G Skipwith; X Long Zheng
Journal:  Blood       Date:  2010-01-14       Impact factor: 22.113

7.  von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size.

Authors:  S-Y Jin; C G Skipwith; D Shang; X L Zheng
Journal:  J Thromb Haemost       Date:  2009-08-11       Impact factor: 5.824

8.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

Authors:  Jing-fei Dong; Joel L Moake; Leticia Nolasco; Aubrey Bernardo; Wendy Arceneaux; Corie N Shrimpton; Alicia J Schade; Larry V McIntire; Kazuo Fujikawa; José A López
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

9.  Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Authors:  Thomas J Raife; Wenjing Cao; Bonnie S Atkinson; Bruce Bedell; Robert R Montgomery; Steven R Lentz; George F Johnson; X Long Zheng
Journal:  Blood       Date:  2009-06-18       Impact factor: 22.113

10.  An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.

Authors:  Wouter Pos; James T B Crawley; Rob Fijnheer; Jan Voorberg; David A Lane; Brenda M Luken
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

View more
  15 in total

1.  Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols.

Authors:  Jenny K McDaniel; Mohammad S Abdelgawwad; Audra Hargett; Matthew B Renfrow; Khalil Bdeir; Wenjing Cao; Douglas B Cines; X Long Zheng
Journal:  J Thromb Haemost       Date:  2019-03-13       Impact factor: 5.824

2.  ADAMTS13 and von Willebrand factor interactions.

Authors:  Catherine B Zander; Wenjing Cao; X Long Zheng
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 3.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 4.  The intertwined fates of inflammation and coagulation in glioma.

Authors:  Angela Cho; Kelly J McKelvey; Adrian Lee; Amanda L Hudson
Journal:  Mamm Genome       Date:  2018-07-30       Impact factor: 2.957

Review 5.  Getting a good view: in vitro imaging of platelets under flow.

Authors:  Oluwamayokun Oshinowo; Tamara Lambert; Yumiko Sakurai; Renee Copeland; Caroline E Hansen; Wilbur A Lam; David R Myers
Journal:  Platelets       Date:  2020-02-28       Impact factor: 3.862

Review 6.  Utility of microfluidic devices to study the platelet-endothelium interface.

Authors:  Jevgenia Zilberman-Rudenko; Joanna L Sylman; Kathleen S Garland; Cristina Puy; Andrew D Wong; Peter C Searson; Owen J T McCarty
Journal:  Platelets       Date:  2017-03-30       Impact factor: 3.862

7.  Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: comment.

Authors:  W J Cao; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-02-06       Impact factor: 5.824

8.  High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.

Authors:  Veronica C Casina; Wenbing Hu; Jian-Hua Mao; Rui-Nan Lu; Hayley A Hanby; Brandy Pickens; Zhong-Yuan Kan; Woon K Lim; Leland Mayne; Eric M Ostertag; Stephen Kacir; Don L Siegel; S Walter Englander; X Long Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-22       Impact factor: 11.205

9.  Transfusion of Platelets Loaded With Recombinant ADAMTS13 (A Disintegrin and Metalloprotease With Thrombospondin Type 1 Repeats-13) Is Efficacious for Inhibiting Arterial Thrombosis Associated With Thrombotic Thrombocytopenic Purpura.

Authors:  Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-11       Impact factor: 8.311

Review 10.  Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis.

Authors:  Brian R Branchford; Christopher J Ng; Keith B Neeves; Jorge Di Paola
Journal:  Thromb Res       Date:  2015-05-21       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.